Table 3

 Polymorphisms of target antigens and coagulation factors other than HLA in different populations of patients with APS

ReferencePatients (n)EthnicityPolymorphisms
Delrieu et al (1999)45171 SLE, 88 primary 
 >APS, 193 controlsFrench whitesPoly(ADP-ribose) polymerase alleles do not influence susceptibility to SLE or primary APS in French white subjects
Hirose et al (1999)31149Whites, African American, AsiansIn Asian patients with APS, expression of a Val at position 247, especially in the homozygous state, is significantly associated with the presence of anti-β2GPI antibodies
Atsumi et al (1999)7088Caucasoidβ2GPI polymorphism, Val/Leu 247, is correlated with anti-β2GPI antibody production in patients with primary APS, and Val 247 may be important in the formation of β2GPI antigenicity
Ruiz-Arguelles et al (1999)4314Mexican mestizoThe G20210A polymorphism (the G→A mutation at nucleotide position 20210) in the 3′-untranslated region of the PT gene in Mexican mestizo patients with APS does not seem to be related to the thrombophilia seen in these patients
Yasuda et al (2002)9477 Japanese and 82 
 >British patients 
 >with aPLJapanese and BritishPolymorphisms of the tissue plasminogen activator and plasminogen activator inhibitor-1 genes probably do not significantly influence the risk of arterial thrombosis, venous thrombosis, or pregnancy morbidity in patients with aPL
Prieto et al (2003)7139 primary APS, 106 healthy controlsMexicanAnti-β2GPI positive patients had significantly higher frequencies of the Val/Val genotype and Val allele expression than control subjects and the β2GPI negative patients 
 >The Val/Val genotype at position 247 of the β2GPI gene may have a role in the generation of anti-β2GPI antibodies and perhaps in the expression of arterial thrombosis in primaryAPS
Camilleri et al (2003)30230WhiteSignificantly decreased prevalence of the Ser316 allele in aPL negative women (n = 98) in comparison with female normal control subjects